- Home
- ACCS vs PLUR Comparison
ACCS vs PLUR Comparison
Compare ACCS & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACCS | PLUR |
|---|---|---|
| Founded | 1988 | 2001 |
| Country | United States | Israel |
| Employees | 91 | 142 |
| Industry | Publishing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 25.5M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | ACCS | PLUR |
|---|---|---|
| Price | $6.03 | $2.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | $12.00 |
| AVG Volume (30 Days) | 11.4K | ★ 15.0K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | $7.40 | $97.38 |
| Revenue Next Year | $8.75 | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $5.99 | $2.22 |
| 52 Week High | $13.35 | $5.96 |
Technical Indicators
Market Signals| Indicator | ACCS | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 31.22 | 33.53 |
| Support Level | N/A | $2.22 |
| Resistance Level | $8.76 | $2.60 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 0.95 | 13.73 |
Price Performance
Historical ComparisonAbout ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.